Safety testing of metabolites: Expectations and outcomes

Chemico-Biological Interactions

Volumn 179, Issue 1, 2009, Pages 45-59

  Pang, K Sandy ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Area under the curve; Intestine, liver and kidney transporter and enzymes; Modeling; Physiologically based pharmacokinetic models; Precursor or metabolite; Preformed and formed metabolite kinetics; Risk assessment; Toxicity and safety

Indexed keywords

ACICLOVIR; ATORVASTATIN; ATRAZINE; BROMISOVAL; CARRIER PROTEIN; CYTOCHROME P450 ISOENZYME; DIAZEPAM; DICHLOROMETHANE; DRUG METABOLIZING ENZYME; ENALAPRIL; ENALAPRILAT; ESTRONE; ESTRONE SULFATE; ETACRYNIC ACID; GENTISAMIDE; GLUCURONIDE; HIPPURIC ACID; MORPHINE; NORDAZEPAM; OXAZEPAM; PARACETAMOL; PARACETAMOL SULFATE; PHENACETIN; PRODRUG; SALICYLAMIDE; SALICYLAMIDE SULFATE; SIMVASTATIN; STYRENE; TEMAZEPAM; TRICHLOROETHYLENE;

APICAL MEMBRANE; AREA UNDER THE CURVE; BASOLATERAL MEMBRANE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG TRANSFORMATION; DRUG TRANSPORT; FLOW RATE; HUMAN; INTESTINE; INTESTINE ABSORPTION; KIDNEY; KIDNEY FUNCTION; LIVER; MODEL; NONHUMAN; PASSIVE TRANSPORT; REVIEW; RISK ASSESSMENT; STOMACH EMPTYING; TOXICITY TESTING;

ANIMALS; AREA UNDER CURVE; HUMANS; INTESTINES; KIDNEY; LIVER; PHARMACOKINETICS; TOXICITY TESTS;

ANIMALIA;

EID: 59649103035     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2008.09.013     Document Type: Review

References (125)

1. FDA guidance for Industry, Safety Testing of Drug Metabolites, February 2008 Pharmacology and Toxicology, http://www.fda.gov/cder/guidance/.
2. Baillie T.A., Cayen M.N., Founda H., Gerson R.J., Green J.D., Grosman S.J., Klunk L.J., LeBlanc B., Perkins D.G., and Shipley L.A. Contemporary issues in toxicology. Drug metabolites in safety. Toxicol. Appl. Pharmacol. 182 (2002) 188-196
3. Smith D.A., and Obach R.S. Commentary. Seeing through the MIST: abundance versus percentage, commentary on metabolites in safety testing. Drug Metab. Dispos. 33 (2005) 1409-1417
4. Smith D.A., and Obach R.S. Metabolites and safety: what are the concerns, and how should we address them?. Chem. Res. Toxicol. 19 (2006) 1570-1579
5. Pang K.S., Morris M.E., and Sun H. Formed and preformed metabolites: facts and comparisons. J. Pharm. Pharmacol. 60 (2008) 1247-1275
6. Prueksaritanont T., Lin J.H., and Baillie T.A. Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites. Toxicol. Appl. Pharmacol. 217 (2006) 143-152
7. Pang K.S., and Gillette J.R. Sequential first-pass elimination of a metabolite derived from a precursor. J. Pharmacokinet. Biopharm. 7 (1979) 275-290
8. Pang K.S. A review of metabolite kinetics. J. Pharmacokinet. Biopharm. 13 (1985) 632-662
9. Pang K.S. Kinetics of sequential metabolism: contribution of parallel, primary metabolic pathways to the formation of a common, secondary metabolite. Drug Metab. Dispos. 23 (1995) 166-177
10. Rappaport A.M. The structural and functional unit in the human liver (liver acinus). Anat. Rec. 130 (1958) 673-689
11. Pang K.S. The effect of intercellular distribution of drug metabolizing enzymes on the kinetics of stable metabolite formation and elimination by the liver: first pass effects. Drug Metab. Rev. 14 (1983) 61-76
12. Pang K.S., and Terrell J.A. Conjugation kinetics of acetaminophen by the perfused rat liver preparation. Biochem. Pharmacol. 30 (1981) 1959-1965
13. Pang K.S., and Gillette J.R. Kinetics of metabolite formation and elimination in the perfused rat liver preparation: differences between the elimination of preformed acetaminophen and acetaminophen formed from phenacetin. J. Pharmacol. Exp. Ther. 207 (1978) 178-194
14. St-Pierre M.V., van den Berg D., and Pang K.S. Physiological modeling of drug and metabolite: disposition of oxazepam and oxazepam glucuronides in the recirculating, perfused rat liver preparation. J. Pharmacokinet. Biopharm. 18 (1990) 423-448
15. St-Pierre M.V., and Pang K.S. Kinetics of sequential metabolism. I. Formation and metabolism of oxazepam from nordiazepam and temazepam in the perfused murine liver. J. Pharmacol. Exp. Ther. 265 (1993) 1429-1436
16. St-Pierre M.V., and Pang K.S. Kinetics of sequential metabolism of metabolites. II. Formation and metabolism of nordiazpeam and oxazepam from diazepam in the perfused murine liver. J. Pharmacol. Exp. Ther. 265 (1993) 1437-1445
17. Schwab A.J., Tao L., Yoshimura T., Simard A., Barker F., and Pang K.S. Hepatic uptake and metabolism of benzoate: a multiple indicator dilution, perfused rat liver study. Am. J. Physiol. 289 (2001) G1124-G1136
18. Tirona R., and Pang K.S. Sequestered endoplasmic reticulum space for sequential metabolism of salicylamide: coupling of hydroxylation and glucuronidation. Drug Metab. Dispos. 24 (1996) 821-833
19. Xu X., and Pang K.S. Hepatic modeling of metabolite kinetics in sequential and parallel pathways: salicylamide and gentisamide metabolism in perfused rat liver. J. Pharmacokinet. Biopharm. 17 (1989) 645-671
20. Morris M.E., Yuen V., Tang B.K., and Pang K.S. Competing pathways in drug metabolism. I. Effect of input concentration on the conjugation of gentisamide in the once-through in situ perfused rat liver preparation. J. Pharmacol. Exp. Ther. 245 (1988) 614-624
21. Morris M.E., Yuen V., and Pang K.S. Competing pathways in drug metabolism. II. An identical, anterior enzymatic distribution for 2- and 5-sulfoconjugation and a posterior localization for 5-glucuronidation of gentisamide in the rat liver. J. Pharmacokinet. Biopharm. 16 (1988) 633-656
22. Tan E., Lu T., and Pang K.S. Futile cycling of estrone sulfate and estrone in the recirculating, perfused rat liver. J. Pharmacol. Exp. Ther. 297 (2001) 423-436
23. Goresky C.A., Pang K.S., Schwab A.J., Barker 3rd F., Cherry W.F., and Bach G.G. Uptake of a protein-bound polar compound, acetaminophen sulfate, by perfused rat liver. Hepatology 15 (1992) 173-190
24. Xu X., Tang B.K., and Pang K.S. Sequential metabolism of salicylamide exclusively to gentisamide-5-glucuronide and not gentisamide sulfate conjugates in single pass in situ perfused rat liver. J. Pharmacol. Exp. Ther. 253 (1990) 963-973
25. Xu X., Schwab A.J., Barker 3rd F., Goresky C.A., and Pang K.S. Salicylamide sulfate cell entry in perfused rat liver: a multiple indicator dilution study. Hepatology 19 (1994) 229-244
26. Ratna S., Chiba M., Bandyopadhyay L., and Pang K.S. Futile cycling between 4-methylumbelliferone and its conjugates in perfused rat liver. Hepatology 17 (1993) 838-853
27. Doherty M., Poon K., Tsang C., and Pang K.S. Transport is not rate-limiting in morphine glucuronidation in the single pass perfused rat liver preparation. J. Pharmacol. Exp. Ther. 317 (2006) 890-900
28. Tirona R.G., Tan E., Meier G., and Pang K.S. Uptake and glutathione conjugation of ethacrynic acid and efflux of the glutathione adduct by periportal and perivenous rat hepatocytes. J. Pharmacol. Exp. Ther. 291 (1999) 1210-1219
29. Polhuijs M., Meijer D.K., and Mulder G.J. The fate of diastereomeric glutathione conjugates of alpha-bromoisovalerylurea in blood in the rat in vivo and in the perfused liver. Stereoselectivity in biliary and urinary excretion. J. Pharmacol. Exp. Ther. 256 (1991) 458-461
30. Polhuijs M., Gasinska I., Cherry W.F., Mulder G.J., and Pang K.S. Stereoselectivity in glutathione conjugation and amidase catalyzed hydrolysis of the 2-bromoisovalerylurea enantiomers in the single pass perfused rat liver. J. Pharmacol. Exp. Ther. 265 (1993) 1402-1412
31. de Lannoy I.A.M., and Pang K.S. Combined recirculation of the rat liver and kidney: studies with enalapril and enalaprilat. J. Pharmacokinet. Biopharm. 21 (1993) 423-456
32. de Lannoy I.A.M., Barker III F., and Pang K.S. Formed and preformed metabolite excretion clearances in liver, a metabolite formation organ: studies on enalapril and enalaprilat in the single-pass and recirculating perfused rat liver. J. Pharmacokinet. Biopharm. 21 (1993) 395-422
33. de Lannoy I.A.M., and Pang K.S. Presence of a diffusional barrier on metabolite kinetics: enalaprilat as a generated versus preformed metabolite. Drug Metab. Dispos. 14 (1986) 513-520
34. Liu L., and Pang K.S. An integrated approach to model hepatic drug clearance. Eur. J. Pharm. Sci. 29 (2006) 215-230
35. Sun H., Liu L., and Pang K.S. Increased estrogen sulfation of estradiol 17β-d glucuronide in metastatic rat tumor livers. J. Pharmacol. Exp. Ther. 319 (2006) 818-831
36. Pang K.S., Wang P.J., Chung A.F., and Wolkoff A.W. The modified dipeptide enalapril, an angiotensin converting enzyme (ACE) inhibitor, is transported by the rat liver organic anion transport protein (OATP1). Hepatology 28 (1998) 1341-1346
37. Geng W., Schwab A.J., Horie T., Goresky C.A., and Pang K.S. Hepatic uptake of bromosulfophthalein-glutathione in perfused EHBR mutant liver: a multiple indicator dilution study. J. Pharmacol. Exp. Ther. 284 (1998) 480-492
38. Geng W.P., Schwab A.J., Goresky C.A., and Pang K.S. Carrier-mediated uptake and excretion of bromosulfophthalein-glutathione in perfused rat liver: a multiple indicator dilution study. Hepatology 22 (1995) 1188-1207
39. Snel C.A.W., Zhao Y., Mulder G.J., and Pang K.S. Methods for the quantitation of bromosulfophthalein and its glutathione conjugate in biological fluids. Anal. Biochem. 212 (1993) 28-34
40. Zhao Y., Snel C.A., Mulder G.J., and Pang K.S. Localization of glutathione conjugation activities toward bromosulfophthalein in perfused rat liver. Studies with the multiple indicator dilution technique. Drug Metab. Dispos. 21 (1993) 1070-1078
41. Dawson J.R., Weitering J.G., Mulder G.J., Stillwell R.N., and Pang K.S. Alteration of transit time and direction of flow to probe the heterogeneous distribution of conjugating activities for harmol in the perfused rat liver preparation. J. Pharmacol. Exp. Ther. 234 (1985) 691-697
42. Chen J., and Pang K.S. Effect of flow on first-pass metabolism of drugs: single pass studies on 4-methylumbelliferone (4MU) conjugation in the serially perfused rat intestine and liver preparations. J. Pharmacol. Exp. Ther. 280 (1997) 24-31
43. Rowland M., Benet L.Z., and Graham G.G. Clearance concepts in pharmacokinetics. J. Pharmacokinet. Biopharm. 1 (1973) 123-136
44. Wilkinson G.R., and Shand D.G. Commentary: a physiological approach to hepatic drug clearance. Clin. Pharmacol. Ther. 18 (1975) 377-390
45. Pang K.S., and Rowland M. Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cells binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J. Pharmacokinet. Biopharm. 5 (1977) 625-653
46. Mizuno N., Niwa T., Yotsumoto Y., and Sugiyama Y. Impact of drug transporter studies on drug discovery and development. Pharmacol. Rev. 55 (2003) 425-461
47. van Montfoort J.E., Hagenbuch B., Groothuis G.M.M., Koepsell H., Meier P.J., and Meijer D.K. Drug uptake systems in liver and kidney. Curr. Drug Metab. 4 (2003) 185-211
48. van de Water F.M., Masereeuw R., and Russel F.G. Function and regulation of multidrug resistance proteins (MRPs) in the renal elimination of organic anions. Drug Metab. Rev. 37 (2005) 443-471
49. Tamai I., Sai Y., Ono A., Kido Y., Yabuuchi H., Takanaga H., Satoh E., Ogihara T., Amano O., Izeki S., and Tsuji A. Immunohistochemical and functional characterization of pH-dependent intestinal absorption of weak organic acids by the monocarboxylic acid transporter MCT1. J. Pharm. Pharmacol. 51 (1999) 1113-1121
50. Kido Y., Tamai I., Okamoto M., Suzuki F., and Tsuji A. Functional clarification of MCT1-mediated transport of monocarboxylic acids at the blood-brain barrier using in vitro cultured cells and in vivo BUI studies. Pharm. Res. 17 (2000) 55-62
51. Deguchi T., Kouno Y., Terasaki T., Takadate A., and Otagiri M. Differential contributions of rOat1 (Slc22a6) and rOat3 (Slc22a8) to the in vivo renal uptake of uremic toxins in rats. Pharm. Res. 22 (2005) 619-627
52. Geng W., and Pang K.S. Differences in excretion of hippurate, as a metabolite of benzoate and as an administered species, in the single pass isolated perfused rat kidney explained. J. Pharmacol. Exp. Ther. 288 (1999) 597-606
53. Hekman P., and van Ginneken C.A. Kinetic modeling of the renal excretion of iodopyracet in the dog. J. Pharmacokinet. Biopharm. 20 (1982) 77-92
54. Boom S.P., Moons M.M., and Russel F.G. Renal tubular transport of cimetidine in the isolated perfused kidney of the rat. Drug Metab. Dispos. 22 (1994) 148-153
55. Suzuki H., and Sugiyama Y. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur. J. Pharm. Sci. 12 (2000) 3-12
56. Pang K.S. Modeling of intestinal drug absorption: Roles of transporters and metabolic enzymes (Gillette Review Series). Drug Metab. Dispos. 31 (2003) 1507-1519
57. Lown K.S., Mayo R.R., Leichtman A.B., Hsiao H.-L., Turgeon K., Schmiedin-Ren P., Brown M.B., Guo W., Rossi S.J., Benet L.Z., and Watkins P.B. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62 (1997) 48-60
58. Kim R.B., Fromm M.F., Wandel C., Leake B., Wood A.J.J., Roden D.M., and Wilkinson G.R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101 (1998) 289-294
59. Friedrichen G.M., Chen W., Begt M., Thomsen A.E., Christensen S.E., Bagger M.A., Steffarup B., Lee C.P., Smith P.L., and Borchardt R.T. Synthesis of analogs of L-valacyclovir and determination of their substrate activity for the oligopeptide transporter in Caco-2 cells. Eur. J. Pharm. Sci. 16 (2002) 1-13
60. Han H., de Vrueh R.L., Rhie J.K., Covitz K.M., Smith P.L., Lee C.P., Oh D.M., Sadée W., and Amidon G.L. 5′Amino acid esters of antiviral nucleosides, acylclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm. Res. 15 (1998) 1154-1159
61. Li F., Maaq H., and Alfredson T. Prodrug nucleoside analogues for improved oral absorption and tissue targeting. J. Pharm. Sci. 97 (2008) 1109-1134
62. Gandhi M.D., Kansara V., and Mitra A.K. Oral disposition of ganciclovir amino acid ester prodrugs: intestinal absorption and transport. AAPS J. 7 (2005) R6247
63. Tsuda M., Terada T., Irie M., Katsura T., Niida A., Tomita K., Fujii N., and Inui K. Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivative. J. Pharmacol. Exp. Ther. 318 (2006) 455-460
64. Ambrose P.J. Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate. Clin. Pharmacokinet. 9 (1984) 222-238
65. Mauro V.F. Clinical pharmacokinetics and practical applications of simvastatin. Clin. Pharmacokinet. 24 (1993) 195-202
66. Hochman J.H., Pudvah N., Qui J., Yamazaki M., Tang C., Lin J.H., and Prueksaritanont T. Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharm. Res. 21 (2004) 1686-1691
67. Welling P.G. Effects of gastrointestinal disease on drug absorption. In: Benet L.Z., Massoud N., and Gambertoglio J.G. (Eds). Pharmadynamic Basis for Drug Treatment (1984), Raven Press, New York 29-47
68. Oberle R.L., and Amidon G.L. The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon. J. Pharmacokinet. Biopharm. 15 (1987) 529-544
69. Plusquellec Y., Campistron G., Staveris S., Barre J., Jung L., Tillement J.P., and Houin G. A double peak phenomenon in the pharmacokinetics of veralipride after oral administration: a double-site model for drug absorption. J. Pharmacokinet. Biopharm. 15 (1987) 225-239
70. Suttle A.B., Pollack G.M., and Brouwer K.L. Use of a pharmacokinetic model incorporating discontinuous gastrointestinal absorption to examine the occurrence of double peaks in oral concentration-time profiles. Pharm. Res. 9 (1992) 350-356
71. Suttle A.B., and Brouwer K.L.R. Regional gastrointestinal absorption of ranitidine in the rat. Pharm. Res. 12 (1995) 1311-1315
72. Takamatsu N., Welage S.S., Hayashi Y., Yamamoto R.Y., Barnett J.L., Shah V.P., Lesko L.J., Ramachandran C., and Amidon G.L. Variability in cimetidine absorption and plasma double peaks following oral administration in the fasted state in humans: correlation with antral motility. Eur. J. Pharmaceut. Biopharm. 53 (2002) 37-47
73. Basit A.W., Podczeck F., Newton J.M., Waddington W.A., Ell P.J., and Lacey L.F. Influence of polyethylene glycol 400 on the gastrointestinal absorption of ranitidine. Pharm. Res. 19 (2002) 1368-1374
74. Lennernäs H., and Regardh C.G. Evidence for an interaction between the beta-blocker pafenolol and bile salts in the intestinal lumen of the rat leading to dose-dependent oral absorption and double peaks in the plasma concentration-time profile. Pharm. Res. 10 (1993) 879-883
75. Doherty M., and Pang K.S. Route-dependent metabolism of morphine in the vascularly perfused rat intestine preparation. Pharm. Res. 17 (2000) 290-297
76. Paine M.F., Shen D.D., Kunze K.L., Perkins J.D., Marsh C.L., McVicar J.P., Barr D.M., Gilles B.S., and Thummel K.E. First-pass metabolism of midazolam by the human intestine. Clin. Pharmacol. Ther. 60 (1996) 14-24
77. Paine M.F., Khalighi M., Fisher J.M., Shen D.D., Kunze K.L., Marsh C.L., Perkins J.D., and Thummel K.E. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J. Pharmacol. Exp. Ther. 283 (1997) 1552-1562
78. Thummel K.W., O'Shae D., Paine M.F., Shen D.D., Kunze K.L., Perkins J.D., and Wilkinson G.R. Oral first pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther. 59 (1996) 491-502
79. Lown K.S., Kolars J.C., Thummel K.E., Barnett J.L., Kunze K.L., Wrighton S.A., and Watkins P.B. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel, Lack of prediction by the erythromycin breath test. Drug Metab. Dispos. 22 (1994) 947-955
80. Watkins P.B., Murray S.A., Winkelman L.G., Heuman D.M., Wrighton S.A., and Guzelian P.S. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochrome P-450. J. Clin. Invest. 83 (1989) 688-697
81. Greiner B., Eichelbaum M., Fritz P., Kreichgauer H.P., von Richter O., Zundler J., and Kroemer H.K. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 104 (1999) 147-153
82. Svanvik J. Mucosal blood circulation and its influence on passive absorption of the small intestine. Acta Physiol. Scand. Suppl. 385 (1973) 1-44
83. Cong D., Doherty M., and Pang K.S. A new physiologically based segregated flow model to explain route-intestinal metabolism. Drug Metab. Dispos. 28 (2000) 224-235
84. Yang J., Jamei M., Yeo K.R., Tucker G.T., and Rostami-Hodjegan A. Prediction of intestinal first-pass drug metabolism. Curr. Drug Metab. 8 (2007) 676-684
85. Gwilt P.R., Comer S., Chaturvedi P.R., and Waters D.H. The influence of diffusional barriers on presystemic gut elimination. Drug Metab. Dispos. 16 (1988) 521-526
86. Kothare P.A., and Zimmerman C.L. Intestinal metabolism: the role of enzyme localization in phenol metabolite kinetics. Drug Metab. Dispos. 30 (2002) 585-594
87. deVries M.H., hofman G.A., Koster A.S., and Noordhoek J. Systemic intestinal metabolism of 1-naphthol. A study in the isolated vascularly perfused rat small intestine. Drug Metab. Dispos. 17 (1989) 573-578
88. H. Sun, K.S. Pang, Disparity in intestine disposition between formed and preformed metabolites and implications: a theoretical study, Drug Metab. Dispos., in press, 2008 Oct 23 [Epub ahead of print].
89. Zaharko D.S., Dedrick R.L., Bischoff K.B., Longstreth J.A., and Oliverio V.T. Methotrexate tissue distribution: prediction by a mathematical model. J. Natl. Cancer Inst. 46 1971 (1971) 775-784
90. Himmelstein M.W., Carpenter S.C., Evans M.V., Hinderliter P.M., and Kenyon E.M. Modeling of β-chloroprene metabolism: II. The application of physiologically based modelling for cancer dose response analysis. Toxicol. Sci. 79 (2004) 28-37
91. Parrott N., Jones H., Paquerau N., and Lavé T. Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man. Basic Clin. Pharmacol. Toxicol. 96 (2005) 193-199
92. Nestorov I.A., Aarons L.J., Arundel P.A., and Rowland M. Lumping of whole-body physiologically based pharmacokinetic models. J. Pharmcokinet. Biopharm. 26 (1998) 21-46
93. Kawai R., Mathew D., Tanaka C., and Rowland M. Physiologically based pharmacokinetics of cyclosporin A: extension to tissue distribution kinetics in rats and scale up to human. J. Pharmacol. Exp. Ther. 287 (1998) 457-468
94. Houston J.B., and Carlille D.J. Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab. Rev. 29 (1997) 891-922
95. Naritome Y., Terashita S., Kimura S., Suzuki A., Kagayama A., and Sugiyama Y. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab. Dispos. 29 (2001) 1316-1324
96. Naritome Y., Terashita S., Kagayama A., and Sugiyama Y. Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab. Dispos. 31 (2003) 580-588
97. Barter Z.E., Bayliss M.K., Beaune P.H., Boobis A.R., Carlie D.J., Edwards R.J., Houston J.B., Lake B.G., Lipscomb J.C., Pelkonen O.R., Tucker G.T., and Rostami-Hodjegan A. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values on human microsomal protein and hepatocellularity per gram of liver. Curr. Drug Metab. 8 (2007) 33-45
98. Shitara Y., Li A.P., Kato Y., Lu C., Ito K., Itoh T., and Sugiyama Y. Function of uptake transporters for taurocholate and estradiol 17β-d-glucuronide in cryopreserved human hepatocytes. Drug Metab. Pharmacokinet. 18 (2003) 33-41
99. Yamada A., Maeda K., Kamiyama E., Sugiyama D., Kondo T., Shiroyanagi Y., Nakazawa H., Okano T., Adachi M., Schuetz J.D., Adachi Y., Hu Z., Kusuhara H., and Sugiyama Y. Multiple isoforms of drug transporters contributed to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab. Dispos. 35 (2007) 2166-2176
100. Gargas M.L., Tyler T.R., Sweeney L.M., Corley R.A., Weitz K.K., Mast T.J., Pausternbach D.J., and Hays S.M. A toxicokinetic study of inhaled ethylene glycol monomethyl ether (2-ME) and validation of a physiologically based pharmacokinetic model for a pregnant rat and human. Toxicol. Appl. Pharmacol. 165 (2000) 53-62
101. Gargas M.L., Tyler T.R., Sweeney L.M., Corley R.A., Weitz K.K., Mast T.J., Paustenbauch D.J., and Hays S.M. A toxicokinetic study of inhaled ethylene glycol ethyl ether acetate and validation of a physiologically based pharmacokinetic model for at and human. Toxicol. Appl. Pharmacol. 165 (2000) 63-73
102. Sweeney L.M., Andersen M.E., and Gargas M.L. Ethyl acrylate risk assessment with a hybrid computational fluid dynamics and physiologically based nasal dosimetry model. Toxicol. Sci. 79 (2004) 394-403
103. Clewell R.A., Kremer J.J., Williams C.C., Campbell Jr. J.L., Andersen M.E., and Borghoff S.J. Tissue exposures to free and glucuronidated monobutylphthalate in the pregnant and fetal rat following exposure to di-N-butylphthalate: evaluation with a PBPK model. Toxicol. Sci. 103 (2008) 241-259
104. McMullin T.S., Hanneman W.H., Crammer B.K., Tesari J.D., and Andersen M.E. Oral absorption and oxidative metabolism of atrazine in rats evaluated by physiological modeling approaches. Toxicology 240 (2007) 1-14
105. Dobrev I.D., Anderson M.E., and Yang Y.S.H. In Silico toxicology: simulating interaction thresholds for human exposure to mixtures of trichloroethylene, tetrachloroethylene, and 1,1,1-trichloroethane. Environ. Health Perspect. 110 (2002) 1031-1039
106. Andersen M.E., Clewell III H.J., Gargas M.L., Smith F.A., and Reitz R.H. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol. Appl. Pharmacol. 87 (1987) 186-205
107. Sarangapani R., Teeguarden J.G., Cruzan G., Clewell H.J., and Andersen M.E. Physiologically based pharmacokinetic modeling of styrene and styrene oxide respiratory-tract dosimetry in rodents and humans. Inhal. Toxicol. 12 (2002) 789-834
108. Chen C.W., and Blancato J.N. Incorporation of biological information in cancer assessment: example-vinyl chloride. Cell Biol. Toxicol. 5 (1989) 417-444
109. Reitz R.H., Gargas M.L., Andersen M.E., Provan W.M., and Green T.L. Predicting cancer risk from vinyl chloride exposure with a physiologically based pharmacokinetic model. Toxicol. Appl. Pharmacol. 137 (1996) 253-267
110. Clewell H.J., Gentry P.R., Gearhart J.M., Allen B.C., and Andersen M.E. Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK model. Sci. Total Environ. 274 (2001) 37-66
111. Frederick C.B., Bush M.L., Lomax L.G., Black K.A., Finch L., Kimbell J.S., Morgan K.T., Subramanian R.P., Morris J.B., and Ultman J.S. Application of a hybrid computational fluid dynamics model and physiologically based inhalation model for interspecies dosimetry extrapolation of acidic vapors in the upper airways. Toxicol. Appl. Pharmacol. 152 (1998) 211-231
112. Frederick C.B., Lomax L.G., Black K.A., Finch L., Scribner H.E., Kimbell J.S., Morgan K.T., Subramanian R.P., and Morris J.B. Use of a hybrid computational fluid dynamics model and physiologically based inhalation model for interspecies dosimetry comparisons of ester vapors. Toxicol. Appl. Pharmacol. 183 (2002) 23-40
113. Corley R.A., Bartels M.J., Carney E.W., Weitz K.K., Soelberg J.J., Gies R.A., and Thrall K.D. Development of a physiologically based pharmacokinetic model for ethylene glycol and its metabolite, glycolic acid in rats and humans. Toxicol. Sci. 85 (2005) 476-490
114. Corley R.A., Wilson D.M., Hard G.C., Stebbins K.E., Bartels M.J., Soelberg J.J., Dryzga M.D., Gingell R., McMartin K.E., and Snellings W.M. Dosimetry considerations in the enhanced sensitivity of male Wistar rats to chronic ethylene glycol-induced nephrotoxicity. Toxicol. Appl. Pharmacol. 228 (2008) 165-178
115. Pang K.S., Sun H., and Liu S. Interplay between transporters and enzymes. In: Morris M.E., and You G. (Eds). Drug Transporters: Molecular Characterization and Role in Drug Disposition (2007), Wiley and Sons 709-745 (Chapter 23)
116. Abu-Zahra T.N., and Pang K.S. Effect of zonal transport and metabolism on hepatic removal: enalapril hydrolysis in zonal, isolated rat hepatocytes in vitro and correlation with perfusion data. Drug Metab. Dispos. 28 (2000) 807-813
117. Andersen M.E., Birnbaum I.S., Barton H.A., and Eklund C.R. Regional hepatic CYP1A1 and CYP1A2 induction with 2,3,7,8-tetrachlorodibenzo-p-dioxin evaluated with a multicompartment geometric model of hepatic zonation. Toxicol. Appl. Pharmacol. 144 (1997) 145-155
118. Li L.Y., Amidon G.L., Kim J.S., Heimbach T., Kesisoglou F., Topliss J.T., and Fleisher D. Intestinal metabolism promotes regional differences in apical uptake of indinavir: coupled effect of P-glycoprotein and cytochrome P450 3A on indinavir membrane permeability in rat. J. Pharmacol. Exp. Ther. 301 (2002) 586-592
119. Liu S., Tam D., Chen X., and Pang K.S. An unstirred water layer and P-glycoprotein barring digoxin absorption by the perfused rat small intestine preparation: Induction studies with and without pregnenolone 16β-carbonitrile (PCN) induction. Drug Metab. Dispos. 34 (2006) 1468-1479
120. Tam D., Tirona R.G., and Pang K.S. Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption. Drug Metab. Dispos. 31 (2003) 373-383
121. Monks T.J., Anders M.W., Dekant W., Stevens J.L., Lau S.S., and van Balderen P.J. Glutathione conjugate mediated toxicities. Toxicol. Appl. Pharmacol. 106 (1990) 1-19
122. Kim H.S., Cha S.H., Abraham D.G., Cooper A.J., and Endou H. Intranephron distribution of cysteine S-conjugate beta-lyase activity and its implication for hexachloro-1,3-butadiene-induced nephrotoxicity in rats. Arch. Toxicol. 71 (1997) 131-141
123. Tojo A., Sekine T., Nakajima N., Hosoyamada M., Kanai Y., Kimura K., and Endou H. Immunohistochemical localization of multispecific renal organic anion transporter 1 in rat kidney. J. Am. Soc. Nephrol. 10 (1999) 464-471
124. Anzai N., Jutabha P., Enomoto A., Yokoyama H., Nonoguchi H., Hirata T., Shiraya K., He X., Cha S.H., Takeda M., Miyazaki H., Sakata T., Tomita K., Igarashi T., Kanai Y., and Endou H. Functional characterization of rat organic anion transporter 5 (Slc22a19) at the apical membrane of renal proximal tubules. J. Pharmacol. Exp. Ther. 315 (2005) 534-544
125. Yokoyama H., Anzai N., Ljubojevic M., Ohtsu N., Sakata T., Miyazaki H., Nonoguchi H., Islam R., Onozato M., Tojo A., Tomita K., Kanai Y., Igarashi T., Sabolic I., and Endou H. Functional and immunochemical characterization of a novel organic anion transporter Oat8 (Slc22a9) in rat renal collecting duct. Cell Physiol. Biochem. 21 (2008) 269-278